Search

Your search keyword '"Dreicer, Robert"' showing total 1,095 results
Start Over Author "Dreicer, Robert"
1,095 results on '"Dreicer, Robert"'

201. PrE0807 phase Ib feasibility trial of neoadjuvant nivolumab (N)/lirilumab (L) in cisplatin-ineligible muscle-invasive bladder cancer (BC).

Author

Grivas, Petros, primary, Puligandla, Maneka, additional, Cole, Suzanne, additional, Courtney, Kevin Dale, additional, Dreicer, Robert, additional, Gartrell, Benjamin Adam, additional, Cetnar, Jeremy Paul, additional, Dall'era, Marc, additional, Galsky, Matt D., additional, Jain, Rohit K., additional, Maughan, Benjamin Louis, additional, Agarwal, Neeraj, additional, Koshkin, Vadim S, additional, Hahn, Noah M., additional, and Carducci, Michael Anthony, additional

Published
2019
Full Text
View/download PDF

202. Durability of complete response (CR) with atezolizumab (atezo) in locally advanced/metastatic urothelial carcinoma (mUC).

Author

Loriot, Yohann, primary, Balar, Arjun Vasant, additional, Dreicer, Robert, additional, Hoffman-Censits, Jean H., additional, Perez-Gracia, Jose Luis, additional, Petrylak, Daniel Peter, additional, Van Der Heijden, Michiel Simon, additional, Shen, Xiaodong, additional, Zhu, Qian (Cindy), additional, Ding, Beiying, additional, Kaiser, Constanze, additional, and Rosenberg, Jonathan E., additional

Published
2019
Full Text
View/download PDF

203. HSD3B1 and overall survival (OS) in men with low-volume (LV) metastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) or chemohormonal therapy in the CHAARTED Randomized trial.

Author

Hearn, Jason W.D., primary, Sweeney, Christopher, additional, Almassi, Nima, additional, Reichard, Chad A., additional, Reddy, Chandana A., additional, Hobbs, Brian, additional, Jarrard, David Frazier, additional, Chen, Yu-Hui, additional, Dreicer, Robert, additional, Garcia, Jorge A., additional, Carducci, Michael Anthony, additional, DiPaola, Robert S., additional, and Sharifi, Nima, additional

Published
2019
Full Text
View/download PDF

204. 5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors.

Author

Sonpavde, Guru, primary, Manitz, Juliane, additional, Gao, Chen, additional, Hennessy, Daniel, additional, Makari, Doris, additional, Niegisch, Guenter, additional, Rosenberg, Jonathan E., additional, Bajorin, Dean F., additional, Grivas, Petros, additional, Apolo, Andrea B., additional, Dreicer, Robert, additional, Hahn, Noah M., additional, Galsky, Matt D., additional, Necchi, Andrea, additional, Srinivas, Sandy, additional, Powles, Thomas, additional, Gupta, Ashok Kumar, additional, Abdullah, Shaad Essa, additional, and Pond, Gregory Russell, additional

Published
2019
Full Text
View/download PDF

205. Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Author

Pal, Sumanta K., primary, Miller, Michael J., additional, Agarwal, Neeraj, additional, Chang, Susan Marina, additional, Chavez-MacGregor, Mariana, additional, Cohen, Ezra, additional, Cole, Suzanne, additional, Dale, William, additional, Magid Diefenbach, Catherine S., additional, Disis, Mary L., additional, Dreicer, Robert, additional, Graham, David L., additional, Henry, N. Lynn, additional, Jones, Joshua, additional, Keedy, Vicki, additional, Klepin, Heidi D., additional, Markham, Merry Jennifer, additional, Mittendorf, Elizabeth A., additional, Rodriguez-Galindo, Carlos, additional, Sabel, Michael S., additional, Schilsky, Richard L., additional, Sznol, Mario, additional, Tap, William D., additional, Westin, Shannon Neville, additional, and Johnson, Bruce E., additional

Published
2019
Full Text
View/download PDF

206. Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC).

Author

Balar, Arjun Vasant, primary, Dreicer, Robert, additional, Loriot, Yohann, additional, Perez-Gracia, Jose Luis, additional, Hoffman-Censits, Jean H., additional, Petrylak, Daniel Peter, additional, Van Der Heijden, Michiel Simon, additional, Shen, Xiaodong, additional, Ding, Beiying, additional, Ramirez-Montagut, Teresa, additional, and Rosenberg, Jonathan E., additional

Published
2019
Full Text
View/download PDF

207. Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer.

Author

Scher, Howard I., primary, Mccormack, Robert Thomas, additional, Molina, Arturo, additional, Smith, Matthew Raymond, additional, Dreicer, Robert, additional, Saad, Fred, additional, De Wit, Ronald, additional, Fizazi, Karim, additional, Aftab, Dana T., additional, Limon, Ana, additional, Fleisher, Martin, additional, De Bono, Johann S., additional, Kelloff, Gary J., additional, and Heller, Glenn, additional

Published
2019
Full Text
View/download PDF

208. Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

Author

Petrylak, Daniel P., primary, Kantoff, Philip, additional, Vogelzang, Nicholas J., additional, Mega, Anthony, additional, Fleming, Mark T., additional, Stephenson, Joe J., additional, Frank, Richard, additional, Shore, Neal D., additional, Dreicer, Robert, additional, McClay, Edward F., additional, Berry, William R., additional, Agarwal, Manish, additional, DiPippo, Vincent A., additional, Rotshteyn, Yakov, additional, Stambler, Nancy, additional, Olson, William C., additional, Morris, Stephen A., additional, and Israel, Robert J., additional

Published
2019
Full Text
View/download PDF

212. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer

Author

Autio, Karen A., primary, Dreicer, Robert, additional, Anderson, Justine, additional, Garcia, Jorge A., additional, Alva, Ajjai, additional, Hart, Lowell L., additional, Milowsky, Matthew I., additional, Posadas, Edwin M., additional, Ryan, Charles J., additional, Graf, Ryon P., additional, Dittamore, Ryan, additional, Schreiber, Nicole A., additional, Summa, Jason M., additional, Youssoufian, Hagop, additional, Morris, Michael J., additional, and Scher, Howard I., additional

Published
2018
Full Text
View/download PDF

222. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Author

Balar, Arjun V, Galsky, Matthew D, Rosenberg, Jonathan E, Powles, Thomas, Petrylak, Daniel P, Bellmunt, Joaquim, Loriot, Yohann, Necchi, Andrea, Hoffman-Censits, Jean, Perez-Gracia, Jose Luis, Dawson, Nancy A, van der Heijden, Michiel S, Dreicer, Robert, Srinivas, Sandy, Retz, Margitta M, Joseph, Richard W, Drakaki, Alexandra, Vaishampayan, Ulka N, Sridhar, Srikala S, Quinn, David I, Durán, Ignacio, Shaffer, David R, Eigl, Bernhard J, Grivas, Petros D, Yu, Evan Y, Li, Shi, Kadel, Edward E, Boyd, Zachary, Bourgon, Richard, Hegde, Priti S, Mariathasan, Sanjeev, Thåström, AnnChristine, Abidoye, Oyewale O, Fine, Gregg D, Bajorin, Dean F, IMvigor210 Study Group, Balar, Av, Rosenberg, Je, Powles, T, Petrylak, Dp, Bellmunt, J, Loriot, Y, Necchi, A, Hoffman-Censits, J, Perez-Gracia, Jl, Dawson, Na, van der Heijden, M, Dreicer, R, Srinivas, S, Retz, Mm, Joseph, Rw, Drakaki, A, Vaishampayan, Un, Sridhar, S, Quinn, Di, Duran, I, Shaffer, Dr, Eigl, Bj, Grivas, Pd, Yu, Ey, Li, S, Kadel, Ee, Boyd, Z, Bourgon, R, Hegde, P, Mariathasan, S, Thastrom, A, Abidoye, Oo, Fine, Gd, and Bajorin, Df

Subjects
0301 basic medicine, Male, medicine.medical_specialty, Urologic Neoplasms, Metastatic Urothelial Carcinoma, Phases of clinical research, Antineoplastic Agents, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, 03 medical and health sciences, 0302 clinical medicine, Atezolizumab, Internal medicine, Clinical endpoint, medicine, Carcinoma, Biomarkers, Tumor, Humans, Infusions, Intravenous, Response Evaluation Criteria in Solid Tumors, Aged, Aged, 80 and over, Carcinoma, Transitional Cell, business.industry, Contraindications, Antibodies, Monoclonal, General Medicine, Middle Aged, medicine.disease, Discontinuation, Surgery, 030104 developmental biology, Tolerability, 030220 oncology & carcinogenesis, Lymphatic Metastasis, Female, Cisplatin, business
Abstract

Summary Background First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti-programmed death-ligand 1 [PD-L1]) as treatment for metastatic urothelial cancer in cisplatin-ineligible patients. Methods For this single-arm, multicentre, phase 2 study, in 47 academic medical centres and community oncology practices in seven countries in North America and Europe, we recruited previously untreated patients with locally advanced or metastatic urothelial cancer who were cisplatin ineligible. Patients were given 1200 mg intravenous atezolizumab every 21 days until progression. The primary endpoint was independently confirmed objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 (central review), assessed in prespecified subgroups based on PD-L1 expression and in all patients. All participants who received one or more doses of atezolizumab were included in the primary and safety analyses. This study was registered with ClinicalTrials.gov, number NCT02108652. Findings Between June 9, 2014, and March 30, 2015, we enrolled 123 patients, of whom 119 received one or more doses of atezolizumab. At 17·2 months' median follow-up, the objective response rate was 23% (95% CI 16 to 31), the complete response rate was 9% (n=11), and 19 of 27 responses were ongoing. Median response duration was not reached. Responses occurred across all PD-L1 and poor prognostic factor subgroups. Median progression-free survival was 2·7 months (2·1 to 4·2). Median overall survival was 15·9 months (10·4 to not estimable). Tumour mutation load was associated with response. Treatment-related adverse events that occurred in 10% or more of patients were fatigue (36 [30%] patients), diarrhoea (14 [12%] patients), and pruritus (13 [11%] patients). One treatment-related death (sepsis) occurred. Nine (8%) patients had an adverse event leading to treatment discontinuation. Immune-mediated events occurred in 14 (12%) patients. Interpretation Atezolizumab showed encouraging durable response rates, survival, and tolerability, supporting its therapeutic use in untreated metastatic urothelial cancer. Funding F Hoffmann-La Roche, Genentech.

Published
2016

223. Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma

Author

Sonpavde, Guru, Pond, Gregory R., Rosenberg, Jonathan E., Bajorin, Dean F., Regazzi, Ashley M., Choueiri, Toni K., Qu, Angela Q., Niegisch, Guenter, Albers, Peter, Necchi, Andrea, Di Lorenzo, Giuseppe, Fougeray, Ronan, Dreicer, Robert, Chen, Yu-Hui, Wong, Yu-Ning, Sridhar, Srikala S., Ko, Yoo-Joung, Milowsky, Matthew I., Galsky, Matthew D., and Bellmunt, Joaquim

Abstract

In this retrospective analysis, complete remission (CR) of disease occurred in 1.8% of patients receiving salvage systemic therapy for advanced urothelial carcinoma. CR was strongly associated with longer survival, prior cisplatin therapy, and time from prior chemotherapy of ≥ 3 months. Agents inducing CR as salvage therapy should undergo further development, and tumors of patients showing CR should be selected for molecular profiling.

Published
2024
Full Text
View/download PDF

224. Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer.

Author

Zahoor, Haris, Mir, Maria C., Barata, Pedro C., Stephenson, Andrew J., Campbell, Steven C., Fergany, Amr, Dreicer, Robert, and Garcia, Jorge A.

Subjects
BCG immunotherapy, ANEMIA, BLADDER tumors, CANCER relapse, SPONTANEOUS cancer regression, CLINICAL trials, CYSTOSCOPY, IMMUNOSUPPRESSION, RESEARCH funding, SURVIVAL analysis (Biometry), THROMBOCYTOPENIA, VASCULAR endothelial growth factors, CLINICAL trial registries, SYMPTOMS
Abstract

Summary: Purpose Sunitinib is a vascular endothelial growth factor receptor (VEGFR) inhibitor with antitumor activity against bladder cancer. We hypothesized that treatment with sunitinib may decrease progression or recurrence in non-muscle invasive bladder cancer (NMIBC) refractory to intra-vesical BCG. Patients and Methods This is a single-arm phase II study of sunitinib in patients (pts) with NMIBC who progressed after BCG. Treatment included sunitinib 37.5 g daily for 12 weeks followed by 12± 2-week cystoscopy and surveillance for one year. The primary endpoint was the complete response rate at 12 months. Secondary endpoints included recurrence free survival (RFS), progression free survival (PFS), overall survival (OS), and safety of sunitinib. Correlative studies on effects of sunitinib on myeloid derived suppressor cells (MDSC) and humoral immune responses were also performed. This trial was registered on ClinicalTrials.gov, number NCT01118351. Results Between June 2011 and September 2011, 15/19 pts. completed 12 weeks of therapy. The remaining 4 pts. had treatment related adverse events leading to discontinuation of sunitinib with one patient withdrawing consent. On the 12-week cystoscopy, 44% (8/18) of the pts. showed remission, 50% (9/18) progression and 1/18 recurrence. Overall, 22% (4/18) of pts. remained free of progression for >12 months. Grade (G) 4 toxicities were noted in 2 pts. (anemia and thrombocytopenia) while G3 were noted in 58%. Sunitinib resulted in reversal of MDSC mediated immunosuppression. Conclusions In NMIBC refractory to BCG, treatment with sunitinib was safe but not associated with improved clinical outcomes. The immune effects of sunitinib deserve further investigation. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

227. Abstract A055: Racial disparities in metastatic castrate-resistant prostate cancer (mCRPC): Evidence from the Veterans Health Administration (VHA)

Author

Halwani, Ahmad, primary, Rasmussen, Kelli M., additional, Patil, Vikas, additional, Burningham, Zachary, additional, Narayanan, Sujata, additional, Lin, Shih-Wen, additional, Carroll, Susheela, additional, Hsu, Ling-I, additional, Graff, Julie N., additional, Dreicer, Robert, additional, Gupta, Sumati, additional, Low, Clarke, additional, and Sauer, Brian C., additional

Published
2018
Full Text
View/download PDF

228. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)

Author

Monk, Paul, primary, Liu, Glenn, additional, Stadler, Walter M., additional, Geyer, Susan, additional, Huang, Ying, additional, Wright, John, additional, Villalona-Calero, Miguel, additional, Wade, James, additional, Szmulewitz, Russell, additional, Gupta, Shilpa, additional, Mortazavi, Amir, additional, Dreicer, Robert, additional, Pili, Roberto, additional, Dawson, Nancy, additional, George, Saby, additional, and Garcia, Jorge A., additional

Published
2018
Full Text
View/download PDF

229. Reply to C. Ren et al

Author

Heller, Glenn, primary, McCormack, Robert, additional, Kheoh, Thian, additional, Molina, Arturo, additional, Smith, Matthew R., additional, Dreicer, Robert, additional, Saad, Fred, additional, de Wit, Ronald, additional, Aftab, Dana T., additional, Hirmand, Mohammed, additional, Limon-Carrera, Ana, additional, Fizazi, Karim, additional, Fleisher, Martin, additional, de Bono, Johann S., additional, and Scher, Howard I., additional

Published
2018
Full Text
View/download PDF

230. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

Author

Gravis, Gwenaelle, primary, Boher, Jean-Marie, additional, Chen, Yu-Hui, additional, Liu, Glenn, additional, Fizazi, Karim, additional, Carducci, Michael A., additional, Oudard, Stephane, additional, Joly, Florence, additional, Jarrard, David M., additional, Soulie, Michel, additional, Eisenberger, Mario J., additional, Habibian, Muriel, additional, Dreicer, Robert, additional, Garcia, Jorge A., additional, Hussain, Maha H.M., additional, Kohli, Manish, additional, Vogelzang, Nicholas J., additional, Picus, Joel, additional, DiPaola, Robert, additional, and Sweeney, Christopher, additional

Published
2018
Full Text
View/download PDF

232. Patterns of PSA versus clinically progressive disease in the E3805 CHAARTED trial.

Author

Bryce, Alan Haruo, primary, Chen, Yu-Hui, additional, Liu, Glenn, additional, Carducci, Michael Anthony, additional, Jarrard, David Frazier, additional, Garcia, Jorge A., additional, Dreicer, Robert, additional, Hussain, Maha, additional, Eisenberger, Mario A., additional, Kohli, Manish, additional, Hahn, Noah M., additional, Plimack, Elizabeth R., additional, Vogelzang, Nicholas J., additional, Picus, Joel, additional, DiPaola, Robert S., additional, Harshman, Lauren Christine, additional, and Sweeney, Christopher, additional

Published
2018
Full Text
View/download PDF

233. Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210.

Author

Balar, Arjun Vasant, primary, Dreicer, Robert, additional, Loriot, Yohann, additional, Perez-Gracia, Jose Luis, additional, Hoffman-Censits, Jean H., additional, Petrylak, Daniel Peter, additional, Van Der Heijden, Michiel Simon, additional, Ding, Beiying, additional, Shen, Xiaodong, additional, and Rosenberg, Jonathan E., additional

Published
2018
Full Text
View/download PDF

234. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Author

Kyriakopoulos, Christos E., primary, Chen, Yu-Hui, additional, Carducci, Michael A., additional, Liu, Glenn, additional, Jarrard, David F., additional, Hahn, Noah M., additional, Shevrin, Daniel H., additional, Dreicer, Robert, additional, Hussain, Maha, additional, Eisenberger, Mario, additional, Kohli, Manish, additional, Plimack, Elizabeth R., additional, Vogelzang, Nicholas J., additional, Picus, Joel, additional, Cooney, Matthew M., additional, Garcia, Jorge A., additional, DiPaola, Robert S., additional, and Sweeney, Christopher J., additional

Published
2018
Full Text
View/download PDF

235. MP78-07 CLINICAL CHARACTERISTICS ASSOCIATED WITH EARLY PROGRESSION OR LONG-TERM RESPONSE FROM THE PHASE II IMVIGOR210 STUDY: ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

Author

Joseph, Richard W., primary, Loriot, Yohann, additional, Perez-Gracia, Jose Luis, additional, Dreicer, Robert, additional, Petrylak, Daniel P., additional, van der Heijden, Michiel S., additional, Hoffman-Censits, Jean, additional, Shen, Xiadong, additional, Fear, Simon, additional, Pavlova, Julie, additional, and Rosenberg, Jonathan E., additional

Published
2018
Full Text
View/download PDF

236. Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Author

Heymach, John, primary, Krilov, Lada, additional, Alberg, Anthony, additional, Baxter, Nancy, additional, Chang, Susan Marina, additional, Corcoran, Ryan B., additional, Dale, William, additional, DeMichele, Angela, additional, Magid Diefenbach, Catherine S., additional, Dreicer, Robert, additional, Epstein, Andrew S., additional, Gillison, Maura L., additional, Graham, David L., additional, Jones, Joshua, additional, Ko, Andrew H., additional, Lopez, Ana Maria, additional, Maki, Robert G., additional, Rodriguez-Galindo, Carlos, additional, Schilsky, Richard L., additional, Sznol, Mario, additional, Westin, Shannon Neville, additional, and Burstein, Harold, additional

Published
2018
Full Text
View/download PDF

238. New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.

Author

Pond, Gregory Russell, primary, Niegisch, Guenter, additional, Rosenberg, Jonathan E., additional, Dreicer, Robert, additional, Powles, Thomas, additional, Necchi, Andrea, additional, Wei, Xiao X., additional, Grivas, Petros, additional, Balar, Arjun Vasant, additional, Galsky, Matt D., additional, Srinivas, Sandy, additional, Choueiri, Toni K., additional, Bellmunt, Joaquim, additional, Bajorin, Dean F., additional, and Sonpavde, Guru, additional

Published
2018
Full Text
View/download PDF

240. Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials

Author

Heller, Glenn, primary, McCormack, Robert, additional, Kheoh, Thian, additional, Molina, Arturo, additional, Smith, Matthew R., additional, Dreicer, Robert, additional, Saad, Fred, additional, de Wit, Ronald, additional, Aftab, Dana T., additional, Hirmand, Mohammad, additional, Limon, Ana, additional, Fizazi, Karim, additional, Fleisher, Martin, additional, de Bono, Johann S., additional, and Scher, Howard I., additional

Published
2018
Full Text
View/download PDF

243. Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer

Author

Milowsky, Matthew I., Galsky, Matthew D., Webb, Iain J., Petruck, Jesika, Morris, Michael J., Dreicer, Robert, Scher, Howard I., Tse, Kin, Crona, Daniel J., Nanus, David M., George, Daniel J., and Bander, Neil H.

Abstract

This phase 1/2 study evaluated the dose-limiting toxicity and maximum tolerated dose of MLN2704, a humanized monoclonal antibody MLN591 targeting prostate-specific membrane antigen, linked to the maytansinoid DM1 in patients with progressive metastatic castration-resistant prostate cancer.

Published
2016
Full Text
View/download PDF

245. Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial

Author

Bryce, Alan H., Chen, Yu Hui, Liu, Glenn, Carducci, Michael A., Jarrard, David M., Garcia, Jorge A., Dreicer, Robert, Hussain, Maha, Eisenberger, Mario Alfredo, Plimack, Elizabeth R., Vogelzang, Nicholas J., DiPaola, Robert S., Harshman, Lauren, and Sweeney, Christopher J.

Abstract

ECOG3805 is a randomized trial of testosterone suppression with or without docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC). Deeper prostate-specific antigen (PSA) suppression is prognostic for outcome. However, the concordance of PSA rise and radiographic progression has not been examined previously in mHSPC, whereas this has been reported in metastatic castration-resistant prostate cancer.

Published
2020
Full Text
View/download PDF

246. Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary

Author

Chang, Sam S., primary, Bochner, Bernard H., additional, Chou, Roger, additional, Dreicer, Robert, additional, Kamat, Ashish M., additional, Lerner, Seth P., additional, Lotan, Yair, additional, Meeks, Joshua J., additional, Michalski, Jeff M., additional, Morgan, Todd M., additional, Quale, Diane Z., additional, Rosenberg, Jonathan E., additional, Zietman, Anthony L., additional, and Holzbeierlein, Jeffrey M., additional

Published
2017
Full Text
View/download PDF

247. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

Author

Chang, Sam S., primary, Bochner, Bernard H., additional, Chou, Roger, additional, Dreicer, Robert, additional, Kamat, Ashish M., additional, Lerner, Seth P., additional, Lotan, Yair, additional, Meeks, Joshua J., additional, Michalski, Jeff M., additional, Morgan, Todd M., additional, Quale, Diane Z., additional, Rosenberg, Jonathan E., additional, Zietman, Anthony L., additional, and Holzbeierlein, Jeffrey M., additional

Published
2017
Full Text
View/download PDF

248. Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1/2 clinical trial.

Author

Garcia, Jorge A., primary, Dreicer, Robert, additional, Pantuck, Allan J., additional, Haas, Naomi B., additional, Vaishampayan, Ulka N., additional, Rao, Niranjan Sathyanarayana, additional, Denis, Louis J., additional, and Tolcher, Anthony W., additional

Published
2017
Full Text
View/download PDF

249. Circulating tumor cell (CTC) number as a response endpoint in metastatic castration resistant (mCRPC) compared with PSA across five randomized phase 3 trials.

Author

Heller, Glenn, primary, Mccormack, Robert Thomas, additional, Kheoh, Thian, additional, Smith, Matthew Raymond, additional, Dreicer, Robert, additional, Saad, Fred, additional, De Wit, Ronald, additional, Aftab, Dana T., additional, Hirmand, Mohammad, additional, MacLean, David B., additional, Fizazi, Karim, additional, De Bono, Johann S., additional, and Scher, Howard I., additional

Published
2017
Full Text
View/download PDF

250. MP53-07 IMPACT OF METFORMIN ON PROSTATE CANCER PC OUTCOMES IN THE E3805 CHAARTED TRIAL

Author

Jarrard, David, primary, Chen, Yu-Hui, additional, Liu, Glenn, additional, Carducci, Michael, additional, Eisenberger, Mario, additional, Wong, Yu-Ning, additional, Hahn, Noah, additional, Kohli, Manish, additional, Cooney, Matthew, additional, Dreicer, Robert, additional, Vogelzang, Nicholas, additional, Picus, Joel, additional, Shevrin, Daniel, additional, Hussain, Maha, additional, Garcia, Jorge, additional, DiPaola, Robert, additional, and Sweeney, Christopher, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results